Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02), Zacks reports. The business had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.61 million. Taysha Gene Therapies had a negative net margin of 1,201.08% and a negative return on equity of 104.93%.
Taysha Gene Therapies Price Performance
NASDAQ:TSHA traded up $0.18 during midday trading on Tuesday, hitting $2.94. 3,134,003 shares of the stock were exchanged, compared to its average volume of 2,866,510. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $630.03 million, a price-to-earnings ratio of -8.66 and a beta of 0.98. The business has a 50-day moving average price of $2.59 and a two-hundred day moving average price of $2.08. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $3.31.
Insiders Place Their Bets
In other Taysha Gene Therapies news, major shareholder Paul B. Manning bought 750,000 shares of the company's stock in a transaction that occurred on Friday, May 30th. The shares were acquired at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the acquisition, the insider directly owned 2,841,704 shares of the company's stock, valued at $7,814,686. This trade represents a 35.86% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 3.78% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Taysha Gene Therapies stock. Rhumbline Advisers lifted its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 13.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 233,256 shares of the company's stock after acquiring an additional 27,794 shares during the quarter. Rhumbline Advisers owned 0.11% of Taysha Gene Therapies worth $539,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 77.70% of the company's stock.
Wall Street Analysts Forecast Growth
TSHA has been the topic of several analyst reports. Bank of America assumed coverage on Taysha Gene Therapies in a research report on Friday, July 11th. They issued a "buy" rating and a $8.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, July 1st. Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Chardan Capital boosted their price objective on Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Finally, Canaccord Genuity Group raised their target price on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, June 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $8.17.
Get Our Latest Stock Analysis on TSHA
Taysha Gene Therapies Company Profile
(
Get Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.